Mink Therapeutics Ownership
| INKT Stock | USD 8.41 0.49 6.19% |
Mink |
Mink Stock Ownership Analysis
About 75.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.86. Mink Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 28th of January 2025. MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. Mink Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people. To learn more about Mink Therapeutics call Jennifer Buell at 212 994 8250 or check out https://minktherapeutics.com.Besides selling stocks to institutional investors, Mink Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Mink Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Mink Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Mink Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Mink Therapeutics Insider Trades History
About 75.0% of Mink Therapeutics are currently held by insiders. Unlike Mink Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Mink Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Mink Therapeutics' insider trades
Mink Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mink Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mink Therapeutics backward and forwards among themselves. Mink Therapeutics' institutional investor refers to the entity that pools money to purchase Mink Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 4 K | Bank Of America Corp | 2024-09-30 | 2 K | Advisor Group Holdings, Inc. | 2024-09-30 | 1.4 K | Covestor Ltd | 2024-09-30 | 1 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 336 | Jpmorgan Chase & Co | 2024-09-30 | 258 | Northwestern Mutual Wealth Management Co | 2024-09-30 | 190 | Game Plan Financial Advisors, Llc | 2024-09-30 | 170 | Key Financial, Inc. | 2024-09-30 | 43.0 | Vanguard Group Inc | 2024-09-30 | 234.2 K | Longbow Finance Sa | 2024-09-30 | 166.7 K |
Mink Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mink Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mink Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mink Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mink Therapeutics Outstanding Bonds
Mink Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mink Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mink bonds can be classified according to their maturity, which is the date when Mink Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Mink Therapeutics Corporate Filings
8K | 18th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
F3 | 9th of December 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.